Cerus (CERS) – FDA
-
Cerus (CERS) Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets
-
Cerus (CERS) Phase 3 Clinical Trial of INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients Met its Primary Efficacy Endpoint
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to CERS Stock Lookup